MedTrace Logo

Efficacy and Safety of CD5789 (Trifarotene) 50μg/g Cream Versus Vehicle Cream in Acne Vulgaris

NCT02566369 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1208

Last updated 2019-11-12

Study results available
· View outcomes & findings →

Summary

Assessment of the efficacy and safety of CD5789 (trifarotene) 50μg/g cream applied once daily for 12 weeks in subjects with acne vulgaris.

Conditions

  • Acne Vulgaris

Interventions

DRUG

CD5789 (trifarotene) 50μg/g cream

CD5789 (trifarotene) 50µg/g cream applied once daily for 12 weeks.

DRUG

Placebo cream

Placebo cream applied once daily for 12 weeks

Sponsors & Collaborators

  • Galderma R&D

    lead INDUSTRY

Principal Investigators

  • Jerry Tan, MD · Windsor Clinical Research

  • Ulrike Blume-Peytavi, MD · Charité Universitätsmedizin

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
9 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-11-30
Primary Completion
2017-11-14
Completion
2017-11-14

Countries

  • United States
  • Canada
  • Germany
  • Hungary
  • Puerto Rico

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02566369 on ClinicalTrials.gov